ACEA Biosciences has pioneered the development of high-performance microelectronic systems for cell-based assays. Recently, ACEA Biosciences and Roche have entered into an exclusive agreement for the development, OEM supply and distribution for ACEA Bioscience's real-time cell assay technology. ACEA and Roche are developing and marketing on a world-wide basis ACEA's microplate-based biosensor platform for a variety of applications in drug development, toxicology, cancer research, and medical microbiology and virology. ACEA's products are designed to meet the increasing needs of the life science research and drug discovery markets by providing cost-effective, automated, high content, real time detection systems that simplify complex cell-based assay procedures and increase productivity.

The Roche-ACEA current product portfolio includes the RT-CA™ Microplate biosensor platform featuring 16 well and 96 well plates and individual workstations. In addition, a 6 X 96 multi-plate® Station is now available to increase the assay throughput. Using the same microelectronic sensor technology, Roche and ACEA will soon launch the revolutionary real time migration analysis system. The system allows researchers to study the invasiveness of cancer cells in a highly quantitative, microplate- based, label-free, cost effective assay. With its international reach, ACEA Biosciences works closely with scientists throughout the world. Hangzhou, China is the site of ACEA's world-class manufacturing operations. Roche, as ACEA's strategic partner, will assure the timely sales, service, and support of the Roche- ACEA growing product line throughout the world. ACEA Biosciences headquarters is in San Diego, California.